Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.
Researchers found that early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) at 2 years or less leads to significant and sustained improvements in disease activity.
The study, presented at the American College of Rheumatology (ACR) Convergence 2025, analyzed data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023.
- The study aimed to describe the demographic and disease characteristics of children diagnosed with non-sJIA when aged from 0 to 23 months.
Outcomes comparable to patients who received treatment later in life and those not exposed to TNF inhibitors.
Author's summary: Early TNF inhibitor use improves outcomes in nonsystemic JIA patients.
More News
- Éminent -Imminent. Quelle différence ?
- CNN: News and Updates
- Drillship to spark imminent Ivory Coast exploration campaign
- IN PICTURES: Penguins queue in Paris zoo for their bird flu jabs
- TWU Local 234 leaders warn SEPTA strike is imminent
- NFL Week 14 scores, live updates: Inactives, playoff standings, predictions, odds and latest news
- Did Susan Dell get facelift? Photo of Dell CEO’s wife sparks speculation amid Trump account donation announcement
- Navjot Singh Sidhu CM-face remark and political comeback
- B.C. peacocks spared from avian flu cull
- “The Night Agent” Season 3 Release Date